Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Shp2 enzyme blocks protection program, boosts tumor growth

Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way.

20 Mar 2015

Scientists discover how ALL cells mutate to survive chemotherapy

By genomic sequencing of leukemia cells from relapsed patients at different stages, scientists have discovered key details of how acute lymphoblastic leukemia (ALL) cells mutate to survive chemotherapy. These mutations enable the cells to proliferate, causing relapse and often death.

20 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

NCCN panelists discuss on evidence-based decision-making at bedside

On Friday, March 13, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care, the National Comprehensive Cancer Network hosted its second roundtable, Value-Based Decision-Making at the Bedside, which reflected on the tools available to oncology clinicians, such as clinical practice guidelines and pathways, and how the use of these tools has impacted bedside evidence-based decision-making for both physicians and patients, the criteria used to assess shared decision-making, and the relationship between outcomes and cost when determining value.

18 Mar 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists, James P. Allison and Carl H. June, will today receive the Paul Ehrlich and Ludwig Darmstaedter Prize in the Paulskirche in Frankfurt. Both give the patient's own immune system the lasting ability to fight cancer, Allison against late stage melanoma, June against leukemia.

16 Mar 2015

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Kalorama Information estimated the budding market for digital PCR reached 175 million in 2014. The market research publisher said companies will be looking to provide products to increase research and diagnostics in diseases like cancer and neurological disorders.

13 Mar 2015

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

13 Mar 2015

Study: New gene therapy safe, effective for patients with hemophilia B

A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.

12 Mar 2015

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

For infants with severe combined immunodeficiency (SCID), something as simple as a common cold or ear infection can be fatal. Born with an incomplete immune system, kids who have SCID--also known as "bubble boy" or "bubble baby" disease--can't fight off even the mildest of germs.

12 Mar 2015

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy.

12 Mar 2015

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.

12 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

Rare, aggressive subtype of pediatric acute lymphoblastic leukemia has surprisingly few mutations

The St. Jude Children's Research Hospital--Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene. The findings suggest that targeting the alteration is likely the key to improved survival.

9 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

Finding may help advance experimental approach to improving public health

Scientists have discovered a new way to manipulate how cells function, a finding that might help advance an experimental approach to improving public health: DNA vaccines, which could be more efficient, less expensive and easier to store than traditional vaccines.

5 Mar 2015

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology.

28 Feb 2015

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML).

26 Feb 2015

Leukemia News and Research

Further Reading

Shp2 enzyme blocks protection program, boosts tumor growth

Scientists discover how ALL cells mutate to survive chemotherapy

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

NCCN panelists discuss on evidence-based decision-making at bedside

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Study: New gene therapy safe, effective for patients with hemophilia B

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Rare, aggressive subtype of pediatric acute lymphoblastic leukemia has surprisingly few mutations

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Finding may help advance experimental approach to improving public health

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News